ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,401 to 3,420 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Receipt of Risk Stratification Tool Assessment86 of 1,018

27 of 1,034

5.8 points

3.9 to 7.9

2,052NCT03702270

The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal

Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Penicillin Allergy Label Removal45 of 1,018

31 of 1,034

1.4 points

-0.2 to 3.1

2,052NCT03702270

The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal

COVID Watch vs COVID Watch + Pulse Oximeter: Incidence of Remote Monitoring Escalations to Clinician108 of 1,024

242 of 1,025

-13.1 points

-16.3 to -9.8

2,049NCT04581863

COVID-19 Watch + COVID-19 Pulse

COVID Watch vs COVID Watch + Pulse Oximeter: Mortality Among COVID-19 Positive Patients3 of 1,024

5 of 1,025

-0.2 points

-0.9 to 0.4

2,049NCT04581863

COVID-19 Watch + COVID-19 Pulse

COVID Watch vs COVID Watch + Pulse Oximeter: deaths from any cause3 of 1,024

5 of 1,025

-0.2 points

-0.9 to 0.4

2,049NCT04581863

COVID-19 Watch + COVID-19 Pulse

Zoledronic Acid vs Denosumab: Time to First On-Study Skeletal-Related Event (Superiority)372 of 1,020

315 of 1,026

5.8 points

1.7 to 9.8

2,046NCT00321464

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Zoledronic Acid vs Denosumab: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)372 of 1,020

315 of 1,026

5.8 points

1.7 to 9.8

2,046NCT00321464

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Recommended vs Anti-recommended: Inpatient Dialysis39 of 1,002

41 of 1,044

-0.0 points

-1.7 to 1.7

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death190 of 1,002

193 of 1,044

0.5 points

-2.9 to 3.9

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Inpatient Mortality169 of 1,002

185 of 1,044

-0.9 points

-4.1 to 2.4

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Progression to Stage 3 AKI72 of 1,002

66 of 1,044

0.9 points

-1.3 to 3.1

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Progression to Stage 2 AKI91 of 1,002

103 of 1,044

-0.8 points

-3.3 to 1.8

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Discharge on Dialysis28 of 1,002

22 of 1,044

0.7 points

-0.7 to 2.1

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: 14-day Dialysis38 of 1,002

37 of 1,044

0.2 points

-1.4 to 1.9

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: 14-day Mortality72 of 1,002

58 of 1,044

1.6 points

-0.5 to 3.8

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: 30 Day Readmission Rate123 of 1,002

187 of 1,044

-5.6 points

-8.7 to -2.5

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: deaths from any cause169 of 1,002

185 of 1,044

-0.9 points

-4.1 to 2.4

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Recommended vs Anti-recommended: Chart Documentation of AKI442 of 1,002

505 of 1,044

-4.3 points

-8.6 to 0.1

2,046NCT02786277

Learning Alerts for Acute Kidney Injury

Galantamine vs Placebo: serious adverse events129 of 1,024

123 of 1,021

0.6 points

-2.3 to 3.4

2,045NCT00679627

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

aQIV vs Comparator QIV: deaths from any cause1 of 1,027

0 of 1,016

0.1 points

-0.3 to 0.5

2,043NCT05044195

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=171"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=171

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03702270-397bffb7",
        "title": "Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Receipt of Risk Stratification Tool Assessment",
        "summary": "86 of 1018 against 27 of 1034; risk difference 5.8 points, 95% interval 3.9 to 7.9; NCT03702270, The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal",
        "record": "/library/comparisons/NCT03702270-397bffb7",
        "nct_id": "NCT03702270",
        "kind": "outcome",
        "participants": 2052,
        "risk_difference": {
          "value": 0.05836718562965271,
          "lower": 0.03895041823923864,
          "upper": 0.07873449714896583
        },
        "group_1": "86 of 1,018",
        "group_2": "27 of 1,034",
        "difference": "5.8 points",
        "interval": "3.9 to 7.9",
        "trial_title": "The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal"
      },
      {
        "id": "NCT03702270-a4dbfe20",
        "title": "Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Penicillin Allergy Label Removal",
        "summary": "45 of 1018 against 31 of 1034; risk difference 1.4 points, 95% interval -0.2 to 3.1; NCT03702270, The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal",
        "record": "/library/comparisons/NCT03702270-a4dbfe20",
        "nct_id": "NCT03702270",
        "kind": "outcome",
        "participants": 2052,
        "risk_difference": {
          "value": 0.014223664560160821,
          "lower": -0.0022511218563102085,
          "upper": 0.031117035448879116
        },
        "group_1": "45 of 1,018",
        "group_2": "31 of 1,034",
        "difference": "1.4 points",
        "interval": "-0.2 to 3.1",
        "trial_title": "The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=172",
  "request_id": "VDM-G8ip4mFGig5V"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?